FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281624508> ?p ?o ?g. }

• W4281624508 endingPage "3330" @default.
• W4281624508 startingPage "3330" @default.
• W4281624508 abstract "The utilization of fluorescein-guided biopsies has recently been discussed to improve and expedite operative techniques in the detection of tumor-positive tissue, as well as to avoid making sampling errors. In this study, we aimed to report our experience with fluorescein-guided biopsies and elucidate distribution patterns in different histopathological diagnoses in order to develop strategies to increase the efficiency and accuracy of this technique. We report on 45 fluorescence-guided stereotactic biopsies in 44 patients (15 female, 29 male) at our institution from March 2016 to March 2021, including 25 frame-based stereotactic biopsies and 20 frameless image-guided biopsies using VarioGuide®. A total number of 347 biopsy samples with a median of 8 samples (range: 4-18) per patient were evaluated for intraoperative fluorescein uptake and correlated to definitive histopathology. The median age at surgery was 63 years (range: 18-87). Of the acquired specimens, 63% were fluorescein positive. Final histopathology included glioblastoma (n = 16), B-cell non-Hodgkin lymphoma (n = 10), astrocytoma, IDH-mutant WHO grade III (n = 6), astrocytoma, IDH-mutant WHO grade II (n = 1), oligodendroglioma, IDH-mutant and 1p/19q-codeleted WHO grade II (n = 2), reactive CNS tissue/inflammation (n = 4), post-transplantation lymphoproliferative disorder (PTLD; n = 2), ependymoma (n = 1), infection (toxoplasmosis; n = 1), multiple sclerosis (n = 1), and metastasis (n = 1). The sensitivity for high-grade gliomas was 85%, and the specificity was 70%. For contrast-enhancing lesions, the specificity of fluorescein was 84%. The number needed to sample for contrast-enhancing lesions was three, and the overall number needed to sample for final histopathological diagnosis was five. Interestingly, in the astrocytoma, IDH-mutant WHO grade III group, 22/46 (48%) demonstrated fluorescein uptake despite no evidence for gadolinium uptake, and 73% of these were tumor-positive. In our patient series, fluorescein-guided stereotactic biopsy increases the likelihood of definitive neuropathological diagnosis, and the number needed to sample can be reduced by 50% in contrast-enhancing lesions." @default.
• W4281624508 created "2022-06-13" @default.
• W4281624508 creator A5001670070 @default.
• W4281624508 creator A5022565050 @default.
• W4281624508 creator A5037512143 @default.
• W4281624508 creator A5047791048 @default.
• W4281624508 creator A5055434346 @default.
• W4281624508 creator A5070275711 @default.
• W4281624508 creator A5071001563 @default.
• W4281624508 creator A5078246703 @default.
• W4281624508 creator A5081929636 @default.
• W4281624508 creator A5086996328 @default.
• W4281624508 date "2022-06-10" @default.
• W4281624508 modified "2023-10-01" @default.
• W4281624508 title "Correlation of Tumor Pathology with Fluorescein Uptake and MRI Contrast-Enhancement in Stereotactic Biopsies" @default.
• W4281624508 cites W1505168929 @default.
• W4281624508 cites W1985200173 @default.
• W4281624508 cites W2004564033 @default.
• W4281624508 cites W2005858732 @default.
• W4281624508 cites W2015250930 @default.
• W4281624508 cites W2034536646 @default.
• W4281624508 cites W2052116633 @default.
• W4281624508 cites W2070225650 @default.
• W4281624508 cites W2094537778 @default.
• W4281624508 cites W2103739917 @default.
• W4281624508 cites W2125282348 @default.
• W4281624508 cites W2125372543 @default.
• W4281624508 cites W2144727376 @default.
• W4281624508 cites W2366536035 @default.
• W4281624508 cites W2414719940 @default.
• W4281624508 cites W2527718370 @default.
• W4281624508 cites W2560730546 @default.
• W4281624508 cites W2638655373 @default.
• W4281624508 cites W2763896294 @default.
• W4281624508 cites W2779263937 @default.
• W4281624508 cites W2789903232 @default.
• W4281624508 cites W2886867144 @default.
• W4281624508 cites W2890932781 @default.
• W4281624508 cites W2905223314 @default.
• W4281624508 cites W3015933354 @default.
• W4281624508 cites W3111131267 @default.
• W4281624508 cites W3160686790 @default.
• W4281624508 doi "https://doi.org/10.3390/jcm11123330" @default.
• W4281624508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35743401" @default.
• W4281624508 hasPublicationYear "2022" @default.
• W4281624508 type Work @default.
• W4281624508 citedByCount "2" @default.
• W4281624508 countsByYear W42816245082022 @default.
• W4281624508 countsByYear W42816245082023 @default.
• W4281624508 crossrefType "journal-article" @default.
• W4281624508 hasAuthorship W4281624508A5001670070 @default.
• W4281624508 hasAuthorship W4281624508A5022565050 @default.
• W4281624508 hasAuthorship W4281624508A5037512143 @default.
• W4281624508 hasAuthorship W4281624508A5047791048 @default.
• W4281624508 hasAuthorship W4281624508A5055434346 @default.
• W4281624508 hasAuthorship W4281624508A5070275711 @default.
• W4281624508 hasAuthorship W4281624508A5071001563 @default.
• W4281624508 hasAuthorship W4281624508A5078246703 @default.
• W4281624508 hasAuthorship W4281624508A5081929636 @default.
• W4281624508 hasAuthorship W4281624508A5086996328 @default.
• W4281624508 hasBestOaLocation W42816245081 @default.
• W4281624508 hasConcept C121332964 @default.
• W4281624508 hasConcept C126838900 @default.
• W4281624508 hasConcept C142724271 @default.
• W4281624508 hasConcept C2775934546 @default.
• W4281624508 hasConcept C2778015030 @default.
• W4281624508 hasConcept C2778256017 @default.
• W4281624508 hasConcept C2781432949 @default.
• W4281624508 hasConcept C2989005 @default.
• W4281624508 hasConcept C544855455 @default.
• W4281624508 hasConcept C62520636 @default.
• W4281624508 hasConcept C71924100 @default.
• W4281624508 hasConcept C91881484 @default.
• W4281624508 hasConceptScore W4281624508C121332964 @default.
• W4281624508 hasConceptScore W4281624508C126838900 @default.
• W4281624508 hasConceptScore W4281624508C142724271 @default.
• W4281624508 hasConceptScore W4281624508C2775934546 @default.
• W4281624508 hasConceptScore W4281624508C2778015030 @default.
• W4281624508 hasConceptScore W4281624508C2778256017 @default.
• W4281624508 hasConceptScore W4281624508C2781432949 @default.
• W4281624508 hasConceptScore W4281624508C2989005 @default.
• W4281624508 hasConceptScore W4281624508C544855455 @default.
• W4281624508 hasConceptScore W4281624508C62520636 @default.
• W4281624508 hasConceptScore W4281624508C71924100 @default.
• W4281624508 hasConceptScore W4281624508C91881484 @default.
• W4281624508 hasIssue "12" @default.
• W4281624508 hasLocation W42816245081 @default.
• W4281624508 hasLocation W42816245082 @default.
• W4281624508 hasLocation W42816245083 @default.
• W4281624508 hasLocation W42816245084 @default.
• W4281624508 hasOpenAccess W4281624508 @default.
• W4281624508 hasPrimaryLocation W42816245081 @default.
• W4281624508 hasRelatedWork W2038159780 @default.
• W4281624508 hasRelatedWork W2076298363 @default.
• W4281624508 hasRelatedWork W2094537778 @default.
• W4281624508 hasRelatedWork W2176016089 @default.
• W4281624508 hasRelatedWork W2358208436 @default.
• W4281624508 hasRelatedWork W236434257 @default.

• next